Clinical Data AZ is three for three with COPD hope tozorakimab PharmaphorumAstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.Clinical DataRespiratoryRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaphorum AstraZeneca’s IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings. Clinical DataRespiratoryRead full story Post navigation Previous: Trump backs psychedelics for mental health in new executive orderNext: The Omnichannel Gap: Building the CRM of the Future for Patient Services Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
